{ Banner Image }

Douglas H. Siegel joins Honigman as a partner in its growing Intellectual Property practice

June 20, 2011

Honigman Miller Schwartz and Cohn LLP (Honigman) is pleased to announce that Douglas H. Siegel has joined the firm as a Partner in its Intellectual Property (IP) Practice Group in the firm’s Corporate and Securities Department. He will be located in Honigman’s Kalamazoo office. Honigman’s IP practice has grown significantly in recent years, with the number of IP attorneys tripling in the last three years. The list of new and lateral IP attorneys at Honigman includes engineers, scientists, biologists, chemists and researchers.

Siegel will focus his practice on life science intellectual property matters. He serves numerous life science industry clients with preparation, prosecution and opinions related to patents, trademarks, trade dress and copyrights. He also litigates these issues in state and federal courts and before administrative tribunals.

Siegel most recently was a Partner at the Grand Rapids IP law firm Price, Heneveld, Cooper, DeWitt & Litton for more than 14 years. For the previous six years, he was a litigator in a Chicago boutique IP firm.

He earned a J.D. from the University of Wisconsin Law School, an M.S. in Cell and Molecular Biology from Michigan State University, and a B.S. in Psychology from the University of Wisconsin-Madison.

Honigman's IP practice, which consists of 33 transactional and litigation attorneys, encompasses a wide variety of patent, trademark, copyright and trade secret issues, including search, registration, enforcement and anti-counterfeiting. The professionals in the IP Practice Group have experience in numerous industries, including automotive (OEM and suppliers), retailing, publishing (newspapers, books, magazines, multi-media), gaming and hospitality, e-commerce, food and beverage, restaurant, advertising, insurance, software, electronics, consumer products, fashion, banking, transportation, telecommunications, medical services and devices, pharmaceuticals, biotechnology, and real estate.